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Abstract
The aim of this work was to describe national surveillance of invasive beta-haemolytic streptococci (BHS) in Denmark and to report
overall trends and major ﬁndings by groups and types of BHS causing laboratory-conﬁrmed disease from 2005 to 2011. A total of 3063
BHS isolates were received from 2872 patients. Based on conﬁrmed cases the overall annual incidence increased from 6.2 to 8.9 per
100 000 persons between 2005 and 2011. In 2011 the incidences of group A, B, C and G streptococci were 3.1, 2.3, 0.9 and 2.6 per
100 000 persons, respectively. An increase was observed for all groups of BHS, but in particular for group G in men above 65 years of
age. Among group A streptococci (GAS), ﬁve T-types (1, 28,12, 3,13,B3264 and B3264) represented 71% and ﬁve emm-types (1, 28, 3, 89
and 12) 76% of all isolates. Among group B streptococci (GBS) four types (III, Ia, V, Ib) represented 79% of the isolates. Potential coverage
for future vaccines against GAS and GBS disease was 76% compared with the 26-valent GAS vaccine and 89% based on GBS serotypes Ia,
Ib, II, III and V. The number of reported cases of invasive BHS disease increased in Denmark from 2005 to 2011. Nationwide
laboratory-based surveillance of BHS is required to monitor epidemiological changes, explore potential outbreaks and determine potential
vaccine coverage.
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Introduction
The beta-haemolytic streptococci (BHS) belonging to the
Lanceﬁeld groups A, B, C and G (GAS, GBS, GCS and GGS,
respectively) cause a broad spectrum of infectious diseases in
humans, ranging from meningitis, sepsis and necrotising fasciitis
to less severe manifestations such as sore throat and wound
infections. The typical clinical presentations vary by serological
group; however, all BHS groups can cause both major and
minor infections [1]. Most infections are community acquired
and outbreaks of GAS, GBS and GGS have been reported in
healthcare-related settings such as maternity wards or care
institutions [2–4].
Laboratory-based surveillance of BHS is relevant because,
due to the severity of BHS manifestations in both adults and
children, there is a need to explore potential outbreaks and to
monitor changes in virulence and potential vaccine coverage.
The aim of this work was to describe national surveillance of
invasive BHS disease in Denmark, overall trends and major
ﬁndings according to groups and types of BHS causing invasive
disease from 2005 to 2011.
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Materials and Methods
Laboratory-based surveillance of BHS in Denmark
The current surveillance system is based on a collaboration
between all departments of clinical microbiology (DCMs) in
Denmark (15 in 2005 and 13 in 2011 as some DCMs have
merged) and the National Neisseria and Streptococcus
Reference (NSR) Laboratory at Statens Serum Institut (SSI).
Nationwide, the DCMs submit isolates from blood, cerebro-
spinal ﬂuid and other normally sterile sites to the NSR on a
voluntary basis. The isolates are referred with information on
the origin of the isolate, including specimen type and date, the
unique personal identiﬁer (CPR number), patient age, sex,
hospital and ward.
Deﬁnitions
A case of invasive BHS disease was deﬁned as isolation of BHS
from a normally sterile site. A new case was deﬁned as an
invasive isolate with a different Lanceﬁeld group within 30 days
from the ﬁrst one or an invasive isolate of any Lanceﬁeld group
more than 30 days after the ﬁrst episode, or the isolation of a
new type (T-type, emm-type or GBS type) if the group was
identical on both occasions.
Bacterial isolates, typing and antibiotic susceptibility testing
The submitted isolates were cultured on 5% horse blood agar
(SSI Diagnostica, Hillerød, Denmark) at 36°C in ambient air
with 5% CO2. The cultures were inspected for purity of
growth, beta-haemolysis and colony morphology, and stored
at 80°C. Invasive BHS isolates were from hospitalized
patients with a few exceptions, as acutely ill patients are
admitted directly to the nearest public hospital in Denmark.
Lanceﬁeld groups A, B, C or G were conﬁrmed by
agglutination tests using Latex grouping reagents A, B, C and
G (Oxoid, Basingstoke, UK) as recommended by the manu-
facturer. For group C isolates fermentation of trehalose or
sorbitol was determined at 36°C overnight (Difco phenol red
medium; SSI Diagnostica) and classiﬁed as S. dysgalactiae
subsp. equisimilis if trehalose was fermented, and as S. equi
subsp. zooepidemicus if sorbitol was fermented [5].
The T-type was determined using type-speciﬁc antisera
(Sevapharma, Prague, Czech Republic) and performed as
recommended by the manufacturer on all GAS isolates, GCS
isolates 2005–2006 and GGS isolates 2005–2007.
Serotyping was performed on all GBS isolates by the latex
agglutination test and the capillary precipitation test using GBS
latex and type-speciﬁc antisera (SSI Diagnostica) as recom-
mended by the manufacturer. GBS isolates from 2008 to 2011
that were non-typable (NT) by these methods or provided an
ambiguous result were also typed with multiplex-PCR using
primers for detection of serotypes Ia, Ib, II, III, IV, V, VI, VIII [6],
VII and IX [7].
The emm sequence-type was determined as described
by Centers for Disease Control and Prevention (CDC) (http://
www.cdc.gov/ncidod/biotech/strep/protocol_emm-type.htm).
All isolates were tested by disc diffusion (Oxoid) for
susceptibility to erythromycin (15 lg), clindamycin (2 lg),
tetracycline (30 lg) and oxacillin/penicillin (1 lg), followed by
MIC determination using Etest (bioMerieux SA, Marcy l’Etoile,
France) on isolates that were non-sensitive on the screening
tests as described by the manufacturers. EUCAST breakpoints
were used (http://www.eucast.org).
Statistical analyses
Information on the size, age and sex distribution of the Danish
population was obtained from Statistics Denmark (www.dst.
dk) (numbers of inhabitants were 5 411 405 in 2005 and
5 560 628 in 2011). We calculated annual incidence rates per
year and by age (0–4, 5–19, 20–64 and ≥65 years) and sex
group. All denominators were the number of inhabitants
within the stratum in question at the beginning of the year. We
divided the study period into an early (2005–2007) and a late
(2009–2011) 3-year period and calculated mean incidence
rates (IRs) for these two periods. Changes during the study
period were ascertained by computing the incidence rate
ratios (IRRs) between the mean incidence rates with a 95%
conﬁdence interval (CI) and a p-value. Two-sided p-values
<0.05 were considered statistically signiﬁcant. For descriptive
purposes we reported medians with interquantile range (IQR).
A test for equality of age between the four serogroups was
carried out using the Kruskal–Wallis test. Analyses were
performed with EpiBasic (available at http://www.folk
esundhed.au.dk/uddannelse/software) and calculations con-
ﬁrmed with Stata 11 (StataCorp, College Station, TX, USA).
Results
From 2005 to 2011 the NSR received 3063 invasive BHS
isolates from 2872 patients, which constituted 2978 cases of
invasive disease.
Overall annual incidences of invasive beta-haemolytic
streptococcal disease
The annual incidence of BHS causing invasive disease in
Denmark increased from 6.2 per 100 000 persons in 2005 to
8.9 in 2011, peaking at 9.2 per 100 000 in 2009. The increase
was statistically signiﬁcant (IRR 1.3, 95% CI 1.2–1.4, p <0.0001)
and it was observed for all groups of BHS (GAS, IRR 1.3, 95%
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CI 1.1–1.5, p 0.0002; GBS, IRR 1.4, 95% CI 1.2–1.6, p 0.0002;
GCS, IRR 2.0, 95% CI 1.5–2.8, p <0.0001; GGS, IRR 1.2, 95%
CI 1.1–1.4, p 0.0015). During the most recent year, 2011, the
annual incidences were 3.1 for GAS, 2.6 for GGS, 2.3 for GBS
and 0.9 for GCS per 100 000 persons (Fig. 1). Most isolates
originated from blood and the proportion of isolates from CSF
was highest for GBS and GAS (Table 1).
Sex, age distributions and age group-related incidences
In the surveillance period a slightly higher proportion of the
BHS isolates originated from men compared with isolates from
women (IRR 1.2, 95% CI 1.1–1.3, p <0.0001). This tendency
was most conspicuous for GGS isolates and statistically
signiﬁcant for all groups (GBS, IRR 1.2, 95% CI 1.0–1.4, p
0.021; GCS, IRR 1.3, 95% CI 1.0–1.7, p 0.030; GGS, IRR 1.5,
95% CI 1.3–1.7, p <0.0001) except for GAS isolates (IRR 1.0,
95% CI 0.9–1.1, p 0.51) (Table 1).
The median age of patients with BHS was 66.2 years;
however, patients with GBS or GAS infections had a lower
median age whereas the median age of patients with GGS
infections was higher, 71.2 years (Table 1).
The age group-related incidence of BHS disease was highest
for adults above 64 years of age and this was the case for all
groups of BHS except GBS (Table 1), where the incidence in
children below 5 years of age was the highest (93.8% of these
children were below 3 months of age). A statistically signiﬁcant
increase in the incidence of BHS disease was observed for all
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FIG. 1. Annual incidences of invasive beta-haemolytic streptococci
(BHS) and group A, B, C and G streptococci (GAS, GBS, GCS and
GGS, respectively) in Denmark from 2005 to 2011.
TABLE 1. Characteristics of invasive beta-haemolytic streptococci (BHS) and group A, B, C and G streptococci (GAS, GBS, GCS
and GGS, respectively) in Denmark from 2005 to 2011
GAS (n = 994) GBS (n = 767) GCS (n = 233) GGS (n = 984) All BHS (n = 2978)
Isolates from clinical material (%)
Blood 93.1 93.2 97.4 96.9 94.7
Cerebrospinal ﬂuid 1.4 4.0 0.4 0.3 1.6
Other sterile material 5.5 2.7 2.2 2.9 3.7
Patient information, age (years)
Median age 63.2 62.2 68.7 71.2 66.2
Age interquartile rangea 42.3–75.2 35.1–75.9 58.0–79.0 60.5–81.7 50.3–78.6
Age range 0–99 0–98 0–100 0–100 0–100
Age group (years) related incidence
0–4 2.54 6.31 0.09 0.35 9.29
5–19 0.45 0.08 0.06 0.06 0.65
20–64 1.95 1.18 0.38 1.51 5.02
≥65 7.56 5.75 2.32 10.36 25.98
All ages 2.59 2.00 0.61 2.56 7.76
Sex and age group (years) related incidence
Incidence in men
0–4 2.31 6.33 0.09 0.43 9.15
5–19 0.49 0.05 0.03 0.05 0.63
20–64 1.90 1.23 0.48 1.75 5.36
≥65 8.23 7.36 2.85 14.34 32.78
All ages 2.54 2.17 0.69 3.09 8.49
Incidence in women
0–4 2.78 6.29 0.09 0.27 9.43
5–19 0.40 0.12 0.09 0.06 0.66
20–64 2.00 1.12 0.28 1.27 4.68
≥65 7.03 4.50 1.91 7.27 20.71
All ages 2.64 1.83 0.52 2.05 7.05
Sex incidence ratio (M:F) 0.96 1.19 1.33 1.51 1.20
Antibiotic resistant (%)
Penicillin 0 0 0.9b 0
Erythromycin 1.9 9.2 1.1 7.7
Clindamycin 0.5 5.4 0.3 1.1
Tetracycline 4.3 48.1 0.3 22.9
aKruskal–Wallis equality-of-populations range test, v2 = 165.011 with 3 d.f., p 0.0001.
bMIC values of two isolates were 0.5 and 1 mg/L and above the breakpoint of 0.25 mg/L; the MIC determinations were conﬁrmed by a different laboratory.
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age groups but one (0–4 years, IRR 1.5, 95% CI 1.1–2.0,
p 0.012; 20–64 years, IRR 1.3, 95% CI 1.1–1.5, p 0.0001;
≥65 years, IRR 1.3, 95% CI 1.1–1.4, p <0.0001); the exception
was the age group 5–19 years (IRR 1.5, 95% CI 0.8–2.9,
p 0.20). The increase was most predominant for GAS and GBS
disease in children below 5 years and for GAS and GBS disease
among adults above 64 years of age (Fig. 2); the increase,
however, was only statistically signiﬁcant for GBS and GCS in
age group 20–64 years and for GAS, GCS and GGS disease in
age group ≥65 years (Appendix S1). The increase was
statistically signiﬁcant for GAS, GBS, GCS and GGS in both
men and women and for some notable subgroups: men aged
≥65 years (GCS and GGS), women aged 20–64 years (GBS,
GCS and GGS) and women aged ≥65 years (GGS).
Invasive GGS infections showed some remarkable charac-
teristics. First of all, the highest annual incidence of BHS
disease (14.3 per 100 000 persons) was observed for this
group in men above 64 years (Table 1), and secondly, there
was a distinct incidence peak in 2009 (Fig. 2) associated with
an incidence among men (19.0 per 100 000), twice as high as in
women (9.2 per 100 000).
Patients with recurrent infection
Three per cent of the patients (n = 88) experienced more
than one episode of invasive disease, 76 patients had two
episodes, nine patients had three episodes and three patients
suffered from four episodes.
Of the 76 patients with two episodes, GGS was the
causative agent of the ﬁrst episode in most patients (47%),
followed by GBS (32%), GAS (13%) and GCS (8%). In 71% of
the patients the recurrent infections were with the same
group, 48% of which were with GGS and 28% with GBS. Of the
22 patients with recurrent infection with a different group, the
ﬁrst episode was caused by GGS followed by GBS or GCS in
ten patients, and caused by GBS followed by GGS or GCS in
eight patients. The recurrence occurred in 33% of patients
between 2 and 3 months after the ﬁrst episode and in 29% of
patients after 3 months but within a year after the ﬁrst
episode.
Of the nine patients with three episodes of infections six
patients had three episodes with GGS, and in the last three
patients GGS caused two or one of the three episodes. Two of
the three patients had four episodes of infections that were
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FIG. 2. Streptococcal group and age group-related incidences of invasive beta-haemolytic streptococci group A, B, C and G streptococci (GAS,
GBS, GCS and GGS, respectively) in Denmark, 2005–2011.
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with the same group (GBS and GCS) and one patient had four
episodes with three different groups (GAS, GCS and GBS).
All of the patients except for one with recurrent infections
were above 19 years of age and most of the patients (66%)
were above 65 years of age and men (68%).
T-type and emm-type distribution among invasive GAS
isolates
Eighteen different T-types were found among the 994 GAS
isolates tested and 13 of these T-types occurred in more than
ﬁve cases. Five T-types represented 71% of the isolates: 1
(25%), 28 (18%), 12 (12%), 3,13,B3264 (9%) and B3264 (7%).
Eleven per cent of the isolates were non-typeable (NT). T-type
1 was the predominant one, varying from 20% in 2007 to 30%
in 2008; exceptions were the years 2005 and 2010, when
T-type 28 was the predominant type, accounting for 25% and
32%, respectively (Fig. 3a).
Fifty-eight different emm-types were found among 910
typed isolates and they comprised 81 types and subtypes. Of
note, only 20 types and subtypes were represented by more
than ﬁve cases. Together, 5 emm-types, 1 (26%), 28 (17%), 3
(13%), 89 (11%) and 12 (9%), represented 76% of the typed
isolates. In most years emm-type 1 was predominant, varying
from 23% to 28% of all isolates, except for the years 2010
when type 28 constituted 31% and 2011 when types 1 and 3
both accounted for 23% of all isolates (Fig 3b).
The 26-valent M-protein vaccine based on the emm-types
1.0, 1.2, 2, 3, 5, 6, 11, 12, 13, 14, 18, 19, 22, 24, 28, 29, 33, 43,
59, 75, 76, 77, 89, 92, 101 and 114 [8] would cover 76% of the
isolates. Combining T- and emm-types, 135 different types
were found, though only 21 occurred in more than ﬁve cases
during the surveillance period. Despite the high diversity
among the typed isolates, 52% were distributed among only
four combinations of T- and emm-types: 1–1 (23%), 28–28
(15%), 12–12.0 (8%) and B3264–89 (6%).
T-type and emm-type distribution among invasive GGS
isolates
Four different T-types were found among the 376 GGS
isolates tested from 2005 to 2007. Of these, 12% were T-type
25 and 5% were T-types 2, 4 or 28. A majority of the isolates
(84%) were non-typable; therefore T-typing of GGS isolates
was discontinued in 2008. Sixty-four different emm-types and
subtypes were found among the 844 typed GGS isolates from
2006 to 2011 and 19 of these types were represented by more
than ﬁve cases. Five emm-types, stG6 (20%), stG485 (16%),
stG643 (13%), stC74a (11%) and stG480 (7%), constituted 66%
of the typed isolates.
Emm-type stG6 was the predominant type, varying from
15% to 21% per year; in 2008 and 2010 type stG480
constituted the same proportion as type stG6 (15% and
17%, respectively, Fig. 4).
The incidence peak of GGS in 2009 was due to an increase
of the existing and already predominant types (Fig. 4) in more
than half of the DCMs and there was no evidence of clustering
within the population serviced by any of the DCMs.
T-type and emm-type distribution among invasive GCS
isolates
In total, 233 invasive GCS isolates were received in the
surveillance period, 94% of these were S. dysgalactiae subsp.
equisimilis and 4% were S. equi subsp. zooepidemicus. Four
different T-types (2, 4, 25 and 28 (one isolate of each)) were
found among the 47 GGS isolates tested from 2005 to 2006. A
major part of the isolates (91%) were NT and T-typing of GCS
isolates was discontinued in 2007. Fourteen different emm--
types were found among the 190 typed GCS isolates from
2006 to 2011 and seven of these types were represented by
more than ﬁve cases. The three emm-types stG62647 (47%),
stG43 (13%) and stG485 (11%) constituted 72% of the isolates.
Type distribution among invasive GBS isolates
All nine known types were found among the 767 GBS isolates.
Seventy-nine per cent of the isolates were represented by the
four types III (34%), Ia (18%), V (15%) and Ib (12%). Nine per
cent of the isolates were NT by the phenotypic testing
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FIG. 3. (a) T-type (A) and emm-type (B) distribution of invasive group
A streptococcal isolates in Denmark from 2005 to 2011.
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methods. From 2008 to 2011, 49 NT isolates were tested by
PCR to determine the type, and the results were included in
the overall type distributions. The predominant type during
the surveillance period was type III, varying from 21% to 44%
of the isolates per year (Fig. 5). A future vaccine based on
serotypes Ia, Ib, II, III and V [9] would potentially cover 89% of
the isolates.
Antibiotic resistance among invasive BHS isolates
The proportions of GAS and GCS isolates resistant to
erythromycin, clindamycin and tetracycline were low (<5%),
whereas the proportions of erythromycin and clindamy-
cin-resistant GBS and GGS isolates ranged from 1.1% to
9.2%. In contrast, almost half of the GBS isolates were resistant
to tetracycline (Table 1). Two group C blood isolates from
2010 were found to have a penicillin MIC value of 0.5 and
1 mg/L (i.e. above the breakpoint of 0.25 mg/L).
Discussion
An increase of invasive BHS disease was observed in Denmark
from 2005 to 2011 based on voluntary submission of invasive
BHS isolates to the national reference laboratory as an integral
part of the Danish surveillance system. In 2011 the incidences
reached 3.1 per 100 000 persons for GAS, 2.6 for GGS, 2.3 for
GBS and 0.9 for GCS. For invasive GAS disease similar
incidence rates have been reported in the UK (3.1 per
100 000), Sweden (3.1) and the USA (3.5) [10,11]). For the
other groups of streptococci, however, the incidences in
Denmark seem to be lower than in comparable populations in
industrialised countries. For example, the incidence of GGS
was 4.3 in Finland and 3.2 in the USA [12,13] and the incidence
of GBS was reported to be higher in the USA (7.3 [14]
including all ages and 7.5 in adults above 17 years [15]); these
incidence differences may at least in part reﬂect differences in
the surveillance methods used.
The number of cases of invasive BHS disease in Denmark is
probably higher than we were able to detect with our current
surveillance system. First of all, patients with invasive BHS
disease but with negative (or missing) cultures will be missed in
this system, and secondly, our surveillance system is based on
voluntary submission of isolates. A previous study from 1999
to 2002 found that on average 79% of GAS, 58% of GBS, 56%
of GCS and 66% of GGS isolates found by the DCMs were
sent to the reference laboratory [16]. The proportion of
isolates submitted may have increased and this can be the
reason for the observed increase in incidence of BHS during
the surveillance period; however, we do not believe that the
peak of invasive GGS in 2009 or the higher proportion of men
with GGS disease results from a changed submission rate
because such a change should affect other groups of BHS as
well. This is supported by an earlier study from the northern
FIG. 4. Emm-type distribution of invasive group G streptococcal
isolates in Denmark from 2006 to 2011.
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part of Denmark reporting a nearly six-fold increase in the
annual incidence of GGS bacteriaemia cases (from 3.0 to 17.2
per 100 000) when comparing 1981–1987 with 1994–1999
[17].
Our study shows that the incidence of invasive BHS disease
is highest among adults above 65 years of age, except for
invasive GBS disease, which is also high among children below
3 months of age.
Typing of invasive GAS isolates showed predominance of T-
and emm-types 1, 3, 89 and 12, which are also common types
in other European countries and the USA [11,18]. Similarly,
the GBS strains causing invasive disease, types Ia, III and V,
have been shown to be major types in the USA [14] and
Sweden [19], and for GCS and GGS isolates the emm-types
stG6, stG485 and stG643 are also predominant types in the
USA [20].
Typing of isolates with respect to components that may be
applied in vaccine formulations such as GBS capsule compo-
nents (the type) and M-protein components (emm-type) may
contribute to decisions on vaccine formulations and help to
estimate vaccine coverage. Our ﬁndings on a potential vaccine
coverage for future vaccines of 76% for the 26-valent GAS
vaccine and 89% for a future GBS vaccine (including serotypes
Ia, Ib, II, III and V) are in accordance with reports from other
countries [9,21].
In conclusion, based on national surveillance of bacterio-
logically conﬁrmed invasive BHS disease we document an
increase over the 7-year period 2005–2011 for all Lanceﬁeld
groups and this is most pronounced for GGS in men. Type
distribution and potential vaccine coverage in Denmark are
compatible with other Western countries. Future studies
should explore in more detail the background of the observed
incidence changes. A recently introduced national database
updated in real-time by the DCMs (The Danish Microbiology
Database (MiBa)) [22] may be useful for future epidemiological
studies. However, continuation of typing and characterization
of BHS isolates is important to explore potential outbreaks,
monitor changes in virulence and evaluate potential vaccine
coverage.
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